AIDS
Conditions
Interventions
TDF-based group:None
TDF-based+ zoledronic acid group:None
TDF-based switched group:None
HIV positive normal bone group:None
HIV positive osteopenia group:None
HIV positive osteoporosis group:None
Sponsors
Beijing Ditan Hospital, Capital Medical University
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Comparison of different real-world scenarios (1) >=18 years old, male (2) HIV antibody positive confirmed by initial screening and immunoblot (Western Blot); (3) Glomerular filtration rate (eGFR) >= 35 ml/min/1.73m²; (4) On antiretroviral therapy for >=1 year (5) Currently receiving TDF-based antiretroviral therapy; (6) Achieved long-term virological suppression after six months of ART, maintaining HIV RNA below the detection limit (=35 ml/min/1.73m²; (4) On antiretroviral therapy for more than 1 year; (5) Viral load <40 copies/ml for 6 consecutive months; (6) Bone density examination results within the past 3 months at the time of enrollment; (7) Voluntarily signed informed consent.
Exclusion criteria
Exclusion criteria: 1. To compare the bone effects of different clinical treatments on osteopenia in adult men with HIV-1/AIDS in the real world 1) co-infection with tuberculosis; 2) patients with hepatitis B or chronic hepatitis C, advanced liver disease, chronic endocrine diseases (hyperthyroidism, diabetes, etc.), chronic malnutrition or malabsorption tumors, osteogenesis implasia; 3) taking medications that may affect bone (e.g., oral glucocorticoids, immunosuppressants, antiepileptic drugs, or anti-osteoporosis drugs) within the past 6 months; 4) hypercalcemia or hypocalcemia. 2. To investigate the effect of chronic inflammation on bone loss from the perspective of immunometabolism 1) co-infection with tuberculosis; 2) patients with hepatitis B or chronic hepatitis C, advanced liver disease, chronic endocrine diseases (hyperthyroidism, diabetes, etc.), chronic malnutrition or malabsorption tumors, osteogenesis implasia; 3) taking medications that may affect bone (e.g., oral glucocorticoids, immunosuppressants, antiepileptic drugs, or anti-osteoporosis drugs) within the past 6 months; 4) poor compliance and long withdrawal time during treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Type I Procollagen N-terminal Propeptide;Type I Collagen Cross-linked C-terminal Peptide;Levels of glucose transporter 1 (GIUT1) in each subpopulation of monocytes;Levels of argininosuccinate synthetase (ASS1) in each subpopulation of monocytes; | — |
Secondary
| Measure | Time frame |
|---|---|
| Bone mineral density;The proportion of regulatory T cells;The proportion of helper T cell 17 subsets; | — |
Countries
China
Contacts
Public ContactHongxin Zhao
Beijing Ditan Hospital, Capital Medical University
Outcome results
None listed